Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Rating) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 359,100 shares, an increase of 49.8% from the April 15th total of 239,700 shares. Based on an average daily volume of 521,900 shares, the days-to-cover ratio is presently 0.7 days. Currently, 5.2% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
Separately, Aegis assumed coverage on Avenue Therapeutics in a research note on Monday, April 3rd. They set a “buy” rating and a $32.00 target price for the company.
Avenue Therapeutics Trading Down 1.0 %
Shares of NASDAQ ATXI opened at $1.03 on Friday. Avenue Therapeutics has a twelve month low of $0.87 and a twelve month high of $16.65. The stock has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.34. The stock has a market cap of $8.16 million, a P/E ratio of -0.58 and a beta of -0.43.
Institutional Investors Weigh In On Avenue Therapeutics
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain.
- Get a free copy of the StockNews.com research report on Avenue Therapeutics (ATXI)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.